Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Mid Cap
Health Score : 8.14J B Chemicals & Pharmaceuticals Ltd. demonstrates exceptional financial health, characterized by outstanding profitability, robust growth, and a very strong, low-debt financial structure. The company excels at generating profits from its sales and provides excellent returns to its shareholders. Its growth in revenue and earnings is remarkable, indicating a strong market position. The company is highly solvent, meaning it has a very low risk associated with debt. The primary area of weakness is in operational efficiency, where the use of assets to generate sales is less effective. While its ability to meet short-term obligations is generally good, its immediate cash reserves are more limited. The future outlook is positive, driven by strong growth and profitability, though its operational efficiency lags behind its otherwise stellar financial performance.
Health Score : 8.14J B Chemicals & Pharmaceuticals Ltd. demonstrates exceptional financial health, characterized by outstanding profitability, robust growth, and a very strong, low-debt financial structure. The company excels at generating profits from its sales and provides excellent returns to its shareholders. Its growth in revenue and earnings is remarkable, indicating a strong market position. The company is highly solvent, meaning it has a very low risk associated with debt. The primary area of weakness is in operational efficiency, where the use of assets to generate sales is less effective. While its ability to meet short-term obligations is generally good, its immediate cash reserves are more limited. The future outlook is positive, driven by strong growth and profitability, though its operational efficiency lags behind its otherwise stellar financial performance.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
57.38
Industry Median
32.74
Mid Cap Median
40.92
P/E RATIO
54.51
P/B RATIO
9.30
Industry Median
3.49
Mid Cap Median
8.10
P/S RATIO
9.35
Industry Median
3.59
Mid Cap Median
7.16
Others
PEG RATIO
4.29
EV/EBITDA RATIO
33.89
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹2408.9 as on Jul 16, 2026.
Growth Score : 10.00The company is experiencing an exceptional phase of growth. It has achieved outstanding increases in its revenue, profits, and earnings for shareholders. This high-growth trend is visible across all key financial areas, from top-line sales to bottom-line net income. The company is also successfully expanding its asset base to support this rapid expansion. This comprehensive and robust growth signals strong market demand for its products and services and effective execution of its business strategy, positioning it well for the future.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 18.65 | 29.91 | 10.64 | 12.46 | 5.87 |
| Operating Profit Growth Rate | -3.04 | 28.18 | 28.88 | 15.05 | 7.27 |
| Earnings Per Share (EPS) Growth | -13.98 | 6.22 | 34.48 | 18.98 | 4.3 |
| Asset Growth Rate | 16.58 | 36.37 | 12.43 | 6.95 | 16.51 |
| Net Income Growth Rate | -14.03 | 6.22 | 34.88 | 19.35 | 7.42 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 49.00 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 2 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 3 | Gland Pharma Ltd | 7.91 | 46.11 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 4 | Neuland Laboratories Ltd | 7.84 | 81.16 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 5 | Granules India Ltd | 7.73 | 34.87 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 6 | Ajanta Pharma Ltd | 7.72 | 41.47 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 7 | Alembic Pharmaceuticals Ltd | 7.60 | 24.58 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 8 | Emcure Pharmaceuticals Ltd | 7.40 | 37.86 | Neutral | 1865.00 | 38.64 | 941.00 |
| 9 | Syngene International Ltd | 7.16 | 51.15 | Neutral | 918.00 | 7.55 | 317.00 |
| 10 | ERIS Lifesciences Ltd | 7.15 | 29.07 | Neutral | 1120.00 | 17.61 | 648.00 |
| 11 | Ipca Laboratories Ltd | 6.33 | 44.19 | Overvalued | 1979.00 | 44.64 | 1184.00 |
| 12 | Piramal Pharma Ltd | 5.83 | -87.02 | Neutral | 922.00 | 5.26 | -326.00 |
| 13 | Jubilant Pharmova Ltd | 5.71 | 36.27 | Neutral | 1260.00 | 1.25 | 398.00 |
| 14 | Natco Pharma Ltd | 5.69 | 10.72 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 15 | Wockhardt Ltd | 5.07 | 141.16 | Neutral | 652.00 | 19.51 | 199.00 |
| 16 | Pfizer Ltd | 3.45 | 46.48 | Neutral | -82.00 | 157.92 | 300.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤21st Jan 26
Q3 FY26 Earnings Conference Call
NEUTRAL SENTIMENT
J B Chemicals & Pharmaceuticals Ltd. is a leading Indian pharmaceutical company manufacturing and marketing a diverse range of formulations. It holds a strong presence in the domestic market across various therapeutic areas, including chronic and acute therapies. The company also exports its products to over 45 countries, focusing on niche segments and contract manufacturing.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. J B Chemicals & Pharmaceuticals Ltd's P/E ratio (TTM) is 57.38, compared to the industry median of 32.74 and large cap median of 40.92.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. J B Chemicals & Pharmaceuticals Ltd's P/B ratio is 9.30, compared to the industry median of 3.49 and large cap median of 8.10.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. J B Chemicals & Pharmaceuticals Ltd's P/S ratio is 9.35, compared to the industry median of 3.59 and large cap median of 7.16.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. J B Chemicals & Pharmaceuticals Ltd's PEG ratio is 4.29.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. J B Chemicals & Pharmaceuticals Ltd's EV/EBITDA ratio is 33.89.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. J B Chemicals & Pharmaceuticals Ltd's ROE is 17.05%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. J B Chemicals & Pharmaceuticals Ltd's ROA is 22.28%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. J B Chemicals & Pharmaceuticals Ltd's ROCE is 26%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. J B Chemicals & Pharmaceuticals Ltd's operating margin is 26.69%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. J B Chemicals & Pharmaceuticals Ltd's net margin is 17.09%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. J B Chemicals & Pharmaceuticals Ltd's current ratio is 2.78.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. J B Chemicals & Pharmaceuticals Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. J B Chemicals & Pharmaceuticals Ltd's interest coverage ratio is 159.67.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. J B Chemicals & Pharmaceuticals Ltd's DPS is ₹9.28.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. J B Chemicals & Pharmaceuticals Ltd's EPS is 4.30.
(Source line: "Ratios as of 27 Sept 2026, based on last traded price of ₹2408.90. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1976 (as J.B. Chemicals & Pharmaceuticals Private Limited)
Headquarters: Mumbai, Maharashtra
Core Offerings: Cardiovascular, Gastrointestinal, Dermatology, Pain Management, Anti-infectives
Stock Listing: NSE (JBCHEPHARM), BSE (506943)
Promoter: KKR (Kohlberg Kravis Roberts & Co. L.P.)
J.B. Chemicals & Pharmaceuticals Private Limited was incorporated in 1976 and went public in 1985. The company steadily expanded its domestic and international footprint over the decades. A pivotal moment occurred in 2020 when KKR, a leading global investment firm, acquired a controlling stake from the Gaba family, signaling a new phase of strategic growth and operational transformation. Since then, the company has focused on strengthening its presence in key therapeutic areas and expanding through strategic acquisitions and product portfolio enhancements.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Domestic Formulations | 55% | Operating Profit |
| International Formulations | 42% | Operating Profit |
| API & Other Businesses | 3% | Operating Profit |
Domestic Formulations: Commands a strong market position in various therapeutic areas such as gastroenterology, cardiology, nephrology, and dermatology. Key brands include Rantac, Metrogyl, Cilacar, and Nicardia, focusing on both prescription-driven chronic and acute therapies.
International Formulations: Engages in exports to over 45 countries, with a strategic focus on contract manufacturing and niche product offerings. Significant presence in key markets like South Africa, the USA, and other emerging economies.
API & Other Businesses: Involved in the manufacturing and sale of Active Pharmaceutical Ingredients (APIs) along with other allied business activities, contributing a smaller but essential portion to the overall revenue.
Shirish M. Bendre (Non-Executive Chairman): Brings extensive experience in the pharmaceutical industry and corporate governance. Nikhil Chopra (CEO & Whole-time Director): An experienced leader with over two decades in the pharmaceutical industry, he has been instrumental in spearheading the company's strategic growth and transformation since joining in 2020.
J.B. Chemicals & Pharmaceuticals (USA) Inc.
JBCP Singapore Pte. Ltd.
Sanzyme Private Limited
2020: KKR acquired a controlling stake (approx. 54%) from the Gaba family for ₹3,100 Crores, marking a significant change in ownership and management direction.
2022: Acquired ophthalmology brands from Dr. Reddy's Laboratories for ₹98 Crores, strengthening its portfolio in a new therapeutic area.
2022: Acquired Sanzyme Private Limited for ₹628 Crores, enhancing its presence in probiotics, nutraceuticals, and other allied segments.
The J B Chemicals & Pharmaceuticals Ltd share price today is ₹2408.90 on NSE (JBCHEPHARM), as of 27 Sept 2026.
As of 27 Sept 2026, J B Chemicals & Pharmaceuticals Ltd share price is ₹2408.90, with previous close ₹2408.90. Today's range is ₹2408.90 to ₹2408.90. The 52-week range is ₹N/A to ₹N/A.
As of today, J B Chemicals & Pharmaceuticals Ltd's market cap is ₹38,783.29 crore (Large Cap).
J B Chemicals & Pharmaceuticals Ltd's current P/E ratio is 57.38, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 38.
J B Chemicals & Pharmaceuticals Ltd's current P/B ratio is 9.30.
J B Chemicals & Pharmaceuticals Ltd's current dividend yield is 0.39%. Last dividend of ₹10.00 per share was declared on 21-Aug-2024.
J B Chemicals & Pharmaceuticals Ltd's EPS (TTM) is ₹4.30.
J B Chemicals & Pharmaceuticals Ltd. is a leading Indian pharmaceutical company manufacturing and marketing a diverse range of formulations. It holds a strong presence in the domestic market across various therapeutic areas, including chronic and acute therapies. The company also exports its products to over 45 countries, focusing on niche segments and contract manufacturing.
J B Chemicals & Pharmaceuticals Ltd is promoted by KKR (Kohlberg Kravis Roberts & Co. L.P.), holding 48.8% as of 27 Sept 2026.
J B Chemicals & Pharmaceuticals Ltd is listed on NSE (JBCHEPHARM) and BSE (506943). Its next quarterly results are expected on August 2024.
Equity Dividend Coverage Ratio
